Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors

Clinical Cancer Research

Volumn 14, Issue 8, 2008, Pages 2458-2464

  Orita, Hajime ^a   Coulter, Jonathan ^a   Tully, Ellen ^a   Kuhajda, Francis P ^a   Gabrielson, Edward ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; PROTEIN KINASE B;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME;

ANIMALS; ANTICARCINOGENIC AGENTS; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; NITROSAMINES; PROTO-ONCOGENE PROTEINS C-AKT; URETHANE;

EID: 42249104519     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4177     Document Type: Article

References (40)

1. Rubins JB, Ewing SL, Leroy S, Humphrey EW, Morrison V. Temporal trends in survival after surgical resection of localized non-small cell lung cancer. Lung Cancer 2000;28:21-7.
2. Dubey S, Schiller JH. Chemotherapy for advanced non-small cell lung cancer. Hematol Oncol Clin North Am 2004;18:101-4.
3. Johnson DH, Sandler A. Treatment of metastatic non-small-cell lung cancer. Chest Surg Clin N Am 2001;11:133-64.
4. Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1993;85:457-64.
5. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000;321:323-9.
6. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: progress and promise. J Natl Cancer Inst 1998;90:1514-28.
7. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000;21:525-30.
8. Hayes RB, Vineis P. Time dependency in human cancer. Tumori 1989;75:189-95.
9. Menendez JA, Lupu R. Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. Curr Opin Clin Nutr Metab Care 2006;9:346-57.
10. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006;66:5977-80.
11. Alli PM, Pinn ML, Jaffee EM, McFadden JM, Kuhajda FP. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 2005;24:39-46.
12. Orita H, Coulter J, Lemmon C, et al. Selective inhibition of fatty acid synthase for lung cancer treatment. Clin Cancer Res 2007;13:7139-45.
13. Belinsky SA, Nikula KJ, Baylin SB, Issa JP. Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. Proc Natl Acad Sci U S A 1996;93:4045-50.
14. Malkinson AM, Beer DS. Major effect on susceptibility to urethan-induced pulmonary adenoma by a single gene in BALB/cBy mice. J Natl Cancer Inst 1983;70:931-6.
15. Loftus TM, Jaworsky DE, Frehywot GL, et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000;288:2379-81.
16. Thupari JN, Landree LE, Ronnett GV, Kuhajda FP. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A 2002;99:9498-502.
17. McFadden JM, Medghalchi SM, Thupari JN, et al. Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase. J Med Chem 2005;48:946-61.
18. Wang HQ, Altomare DA, Skele KL, et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005;24:3574-82.
19. ATBC Cancer Prevention Study Group. The effect of vitamin E and β carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
20. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001;93:605-18.
21. Kelloff GJ, Boone CW, Steele VK, Perloff M, Crowell J, Doody LA. Development of chemopreventive agents for lung and upper aerodigestive tract cancers. J Cell Biochem Suppl 1993;17F:2-17.
22. Lotan R. Retinoids and chemoprevention of aerodigestive tract cancers. Cancer Metastasis Rev 1997;16:349-56.
23. Toma S, Raffo P, Isnardi L, Palumbo R. Retinoids in lung cancer chemoprevention and treatment. Ann Oncol 1999;10:S95-102.
24. Khuri FR, Lippman SM. Lung cancer chemoprevention. Semin Surg Oncol 2000;18:100-5.
25. Dragnev KH, Rigas JR, Dmitrovsky E. The retinoids and cancer prevention mechanisms. Oncologist 2000;5:361-8.
26. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002;41:41-55.
27. Chung EL. Chemoprevention of lung cancer by isothiocyanates and their conjugates in A/J mouse. Exp Lung Res 2001;27:319-30.
28. Liby K, Royce DB, Williams CR, et al. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res 2007;67:2414-9.
29. Granville CA, Warfel N, Tsurutani J, et al. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res 2007;13:2281-9.
30. Kassie F, Anderson LB, Scherber R, et al. Indole-3-carbinol inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo(a)pyrene- induced lung tumorigenesis in A/J mice and modulates carcinogen-induced alterations in protein levels. Cancer Res 2007;67:6502-11.
31. Matzinger SA, Crist KA, Stoner GD, et al. K-ras mutations in lung tumors from A/J and A/J x TSGp53 F1 mice treated with 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone and phenethyl isothiocyanate. Carcinogenesis 1995;16:2487-92.
32. Nuzum EO, Malkinson AM, Beer DG. Specific Ki-ras codon 61 mutations may determine the development of urethan-induced mouse lung adenomas or adenocarcinomas. Mol Carcinog 1990;3:287-95.
33. Stearman RS, Dwyer-Nield L, Zerbe L, et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 2005;167:1763-75.
34. Keith RL, Miller YE, Hudish TM, et al. Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res 2004;64:5897-904.
35. Little JL, Wheeler FB, Fels DR, Koumenis C, Kridel SJ. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res 2007;67:1262-9.
36. Zhou W, Han WF, Landree LE, et al. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res 2007;67:2964-71.
37. Tichelaar JW, Zhang Y, leRiche JC, Biddinger PW, Lam S, Anderson MW. Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies. BMC Cancer 2005;5:155.
38. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004;25:2053-9.
39. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114:1028-35.
40. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996;14:483-510.